As shown in Table S1, HCC cells divided by either TP53 mutation status or CTNNB1 expression level exhibited no significantly different sensitivity to paclitaxel treatment (Figure 5A). This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.